Alirocumab safe in patients with diabetes mellitus PROFICIO analysis shows consistent LDL lowering with evolocumab PROFICIO analysis shows consistent LDL lowering with evolocumab International Atherosclerosis Society and FH Foundation join forces to improve FH management ESC 2018: FOURIER analysis: Greater benefit with evolocumab in metabolic syndrome patients ESC 2018: FOURIER: Evolocumab shows similar benefit in men, women and the elderly Two more analyses show efficacy of alirocumab in diabetes OSLER: sustained benefit with evolocumab in statin intolerant patients

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & Objectives Mission Statement Editorial Board Partnership & Outreach Forthcoming Meetings

Download NowUNIQUE FREE APPAdvances in lipid lowering - a clinical guide

AHA Scientific Sessions
10-12 November, 2018

AHA2018

CHECK BACK FOR REPORTAGE FROM THIS YEAR'S SESSIONS

News from ESC Congress 2018

News from ISA 2018

Most viewed

What are PCSK9 inhibitors? Trials How will PCSK9 inhibitors be used in real world clinical practice? Alirocumab shows efficacy in homozygous FH phenotype Slides Editorial Board Editorial Policy Videos Who could benefit from PCSK9 inhibitors? Events

Most viewed

What are PCSK9 inhibitors?

Lipoprotein(a) – does it matter when LDL cholesterol is low?

Lipoprotein(a) is now recognised as an independent risk factor for cardiovascular disease.

But is it also relevant to consider lipoprotein(a) when LDL cholesterol is low?

Prof. Anthony S Wierzbicki, Guy’s and St Thomas’ Hospitals, London, UK discusses the evidence.

Read the report

Hot Topics

Guidance needed on LDL lowering in very high-risk patients

Do high and very high-risk patients at guideline-recommended goal gain more benefit from further lowering LDL cholesterol levels?

PCSK9 Forum Editor Professor John Chapman (UPMC-Sorbonne, Director Emeritus, INSERM, Paris, France), discusses.

Read the report

Video: Impetus to change LDL-C goal from FOURIER
Watch the video

From the Editors

Is LDL-apheresis still needed in the PCSK9 era?

With the advent of PCSK9 monoclonal antibodies, reduction in LDL-cholesterol levels by up to 80-90% is now possible, when combined with statins and ezetimibe. What role does LDL-apheresis have in this new era?